5-anilino-[1,2,4]dithiazole-3-thione | 56931-20-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-anilino-[1,2,4]dithiazole-3-thione
• 英文别名: 5-Phenylimino-3-thio-1,2,4-dithiazolidin；3-Thio-5-phenylimino-1,2,4,-dithiazolin；5-Anilino-1,2,4-dithiazole-3-thione
• CAS: 56931-20-5
• 化学式: C₈H₆N₂S₃
• 分子量: 226.347
• InChiKey: WXHDPFBBGFZCKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  107
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-anilino-[1,2,4]dithiazole-3-thione 、 氯化苄 以 氯仿 为溶剂， 生成 (5-benzylsulfanyl-[1,2,4]dithiazol-3-ylidene)-phenyl-amine
  参考文献：
  名称：

  Mahajan,A.S.; Paranjpe,M.G., Journal of the Indian Chemical Society, 1975, vol. 52, p. 237 - 239

  摘要：

  DOI：
• 作为产物：
  描述：

  γ-Phenyl-trithioallophanic acid 在 碘 、 potassium iodide 作用下， 以 乙醇 为溶剂， 生成 5-anilino-[1,2,4]dithiazole-3-thione
  参考文献：
  名称：

  Damle,M.H., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1979, vol. 17, p. 17 - 19

  摘要：

  DOI：

文献信息

• Treatment of neurological disorders by dsrna administration
  申请人：Dorn Gabriele

  公开号：US20060030534A1

  公开（公告）日：2006-02-09

  The present invention relates to methods to treat neurological disorders comprising intrathecal injection of an effective amount of a double-stranded (ds) RNA into a subject in need, wherein said dsRNA inhibits the expression of a target gene and to pharmaceutical compositions useful for such treatment.

  本发明涉及治疗神经系统疾病的方法，包括向有需要的受试者鞘内注射有效量的双链 (ds) RNA，其中所述 dsRNA 可抑制靶基因的表达，本发明还涉及用于此类治疗的药物组合物。
• BUTLER A. R.; HUSSAIN I., J. CHEM. RES. SYNOP., 1980, NO 8, 266-267
  作者：BUTLER A. R.、 HUSSAIN I.

  DOI：——

  日期：——
• USE OF MOB-5 IN PAIN
  申请人：Novartis AG

  公开号：EP1492516A2

  公开（公告）日：2005-01-05
• TREATMENT OF CHRONIC NEUROPATHIC PAIN BY ADMISTRATION OF DSRNA
  申请人：Arrowhead Research Corporation

  公开号：EP1551424B1

  公开（公告）日：2015-07-01
• Antisense oligonucleotides directed to genes regulated by trapoxin-induced HDAC inhibition
  申请人：Buxton P. Francis

  公开号：US20060040884A1

  公开（公告）日：2006-02-23

  Antisense compounds, compositions and methods are provided for modulating the expression of trapoxin A regulated genes, including but not limited to those genes induced by ectopic expression of p21 waf1 that are disclosed herein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding these genes. Methods of using these compounds for modulation of expression of these genes and for treatment of diseases associated with these genes, as well as those associated with abnormal HDAC activity, particularly cancer or others characterized by abnormal cell proliferation, are provided. Furthermore, the invention relates to the use of RhoB as a biomarker to evaluate the efficacy of treatment of humans with abnormal HDAC activity including proliferative diseases such as cancer. Also disclosed is a method for identifying HDAC inhibitors and trapoxin analogs based on the surprising discovery that up regulation or RhoB and increased RhoB protein levels are associated with HDAC inhibition.